22,800 Shares in Icon Plc $ICLR Acquired by Militia Capital Management LLC

Militia Capital Management LLC acquired a new stake in Icon Plc (NASDAQ:ICLR) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,800 shares of the medical research company’s stock, valued at approximately $2,523,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Icon by 1.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock valued at $203,800,000 after buying an additional 11,335 shares during the last quarter. Jennison Associates LLC purchased a new stake in Icon in the 4th quarter worth about $123,542,000. Trinity Street Asset Management LLP increased its holdings in Icon by 23.1% in the 4th quarter. Trinity Street Asset Management LLP now owns 1,072,428 shares of the medical research company’s stock worth $195,418,000 after acquiring an additional 201,455 shares during the last quarter. Calamos Advisors LLC bought a new stake in Icon in the 4th quarter valued at about $4,829,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in Icon in the 4th quarter valued at about $2,960,000. 95.61% of the stock is owned by institutional investors.

Icon Stock Up 0.4%

ICLR stock opened at $167.28 on Thursday. The stock has a 50-day simple moving average of $149.05 and a two-hundred day simple moving average of $136.36. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The firm has a market capitalization of $12.81 billion, a PE ratio of 29.77, a PEG ratio of 8.18 and a beta of 1.22. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31.

Wall Street Analyst Weigh In

ICLR has been the subject of a number of research reports. Citigroup increased their target price on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. UBS Group set a $160.00 price target on shares of Icon in a research report on Wednesday, June 24th. TD Cowen upped their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. DA Davidson set a $164.00 price objective on shares of Icon in a research note on Monday, June 1st. Finally, Piper Sandler cut shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $173.19.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.